ArticleExploratory research in clinical and social pharmacy2026
Deprescribing proton pump inhibitors in long-term care: Outcomes of a pharmacist-led initiative.
Article in Exploratory research in clinical and social pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Proton pump inhibitors (PPIs) are frequently continued without clear indication in long-term care (LTC) settings. Evidence-based deprescribing strategies may reduce unnecessary exposure, but real-world data from Middle Eastern LTC facilities remain limited. Objective: To evaluate the feasibility, implementation, and short-term safety of a pharmacist-led PPI deprescribing initiative in a long-term care facility. Methods: This retrospective cohort study included LTC residents receiving PPIs who underwent pharmacist-led medication review between September and November 2024. Residents were classified eligible or ineligible for deprescribing using guideline-aligned criteria. Deprescribing required approval from the attending physician and resident or family. Outcomes included deprescribing implementation, maintenance off PPIs at 3-month follow-up, symptom recurrence, PPI reinitiation, and gastrointestinal (GI) bleeding events. Results: Among 68 residents, 35 (51.5%) were eligible for deprescribing. Deprescribing was implemented in 26 eligible residents (74.3%; 95% CI 56.7-87.5). Sustained PPI discontinuation occurred in 25 of 35 eligible residents (71.4%; 95% CI 53.7-85.4). Among the 26 residents who discontinued therapy, 25 (96.2%; 95% CI 80.4-99.9) remained off PPIs at 3 months. One resident (3.8%; 95% CI 0.1-19.6) had GI bleeding during follow-up. No other adverse events were observed, and no resident required rescue acid-suppressive therapy or urgent evaluation. Conclusion: A pharmacist-led deprescribing initiative was feasible to implement in a long-term care facility and was associated with high deprescribing uptake and maintenance off therapy among eligible residents. These findings support the potential role of pharmacist-led deprescribing in LTC settings and highlight opportunities for further evaluation of deprescribing programs in underrepresented regions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.